The DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.
The time course of epidermal nerve fibre regeneration: studies in normal controls and in people with diabetes, with and without neuropathy
Open accessAbstract
We sought to develop and validate a standardized cutaneous nerve regeneration model and to define the rate of epidermal nerve fibre (ENF) regeneration first in healthy control subjects and then in neuropathic and neuropathy-free subjects with diabetes. Next, we assessed the effect of different factors on the rate of nerve fibre regeneration and investigated whether such an approach might offer insight into novel trial designs and outcome measures. All subjects had a standardized topical capsaicin dressing applied to the distal lateral thigh. ENF densities derived from skin biopsies were determined at baseline, after capsaicin treatment and at reinnervation time points. For each subject, the best fit line from post-denervation data was determined and the slope was used as the rate of regeneration. In healthy control subjects, regeneration was correlated with psychophysical sensory testing, electron microscopy studies and immunohistochemistry with alternative axonal membrane markers. Topical capsaicin application produced complete or nearly complete denervation of the epidermis in both control subjects and people with diabetes. The rate of regeneration was associated with the baseline ENF density (P < 0.001), but not age (P = 0.75), gender (P = 0.18), epidermal thickness (P = 0.4) or post-capsaicin treatment density (P = 0.7). ENF regeneration, as determined by recovery of ENF density, occurred at a rate of 0.177 +/- 0.075 fibres/mm/day in healthy control subjects and was significantly reduced in subjects with diabetes (0.074 +/- 0.064, P < 0.001) after adjusting for changes in baseline ENF density. Among subjects with diabetes, the presence of neuropathy was associated with a further reduction in regenerative rate (0.10 +/- 0.07 versus 0.04 +/- 0.03, P = 0.03), though diabetes type (P = 0.7), duration of diabetes (P = 0.3) or baseline glycated haemoglobin (P = 0.6) were not significant. These results have several implications. First, topical capsaicin application can produce a uniform epidermal nerve fibre injury that is safe and well tolerated, and offers an efficient strategy to measure and study nerve regeneration in man. Secondly, using our techniques, reduced rates of nerve regeneration were found in people with diabetes without evidence of neuropathy and indicate that abnormalities in peripheral nerve function are present early in diabetes, before signs or symptoms develop. These results suggest that regenerative neuropathy trials could include non-neuropathic subjects and that trial duration can be dramatically shortened.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Efficient Analysis of Experimental Observations
Dixon, W. J. (1980) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pa.20.040180.002301 · Cited by 2,208
Feldman, E. L., Stevens, M. J., Thomas, P. K., Brown, M. B., Canal, N., & Greene, D. A. (1994) · Diabetes Care · doi:10.2337/diacare.17.11.1281 · Cited by 1,293
Effect of intensive therapy on the microvascular complications of type 1 diabetes mellitus
The Writing Team for the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group (2002) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.287.19.2563 · Cited by 941
The spectrum of neuropathy in diabetes and impaired glucose tolerance
Sumner, C. J., Sheth, S., Griffin, J. W., Cornblath, D. R., & Polydefkis, M. (2003) · Neurology · doi:10.1212/wnl.60.1.108 · Cited by 708 · cited 1×
“Lastly, these ®bres are clinically relevant as they are implicated in many types of painful neuropathy such as those associated with human immunode®ciency virus (HIV) infection, diabetes mellitus and impaired glucose tolerance (McCarthy et al., 1995; Kennedy et al., 1996; Kennedy, 1996; Smith et al., 2001; Sumner et a…”
BackgroundSelf-citationEpidermal Nerve Fiber Density: Normative Reference Range and Diagnostic Efficiency
McArthur, J. C., Stocks, E. A., Hauer, P., Cornblath, D. R., & Griffin, J. W. (1998) · Archives of Neurology · doi:10.1001/archneur.55.12.1513 · Cited by 560
Self-citationCutaneous innervation in sensory neuropathies: Evaluation by skin biopsy
McCarthy, B. G., Hsieh, S.-T., Stocks, A., Hauer, P., Macko, C., Cornblath, D. R., Griffin, J. W., & McArthur, J. C. (1995) · Neurology · doi:10.1212/wnl.45.10.1848 · Cited by 472
Self-citationTopical capsaicin in humans: parallel loss of epidermal nerve fibers and pain sensation
Nolano, M., Simone, D. A., Wendelschafer-Crabb, G., Johnson, T., Hazen, E., & Kennedy, W. R. (1999) · Pain · doi:10.1016/s0304-3959(99)00007-x · Cited by 469
Quantitation of epidermal nerves in diabetic neuropathy
Kennedy, W. R., Wendelschafer-Crabb, G., & Johnson, T. (1996) · Neurology · doi:10.1212/wnl.47.4.1042 · Cited by 436
Annual Review of Pharmacology,
Williams, J. F. (1975) · Archives of Internal Medicine · doi:10.1001/archinte.1975.00330100136032 · Cited by 386
Simone, D. A., Nolano, M., Johnson, T., Wendelschafer-Crabb, G., & Kennedy, W. R. (1998) · The Journal of Neuroscience · doi:10.1523/jneurosci.18-21-08947.1998 · Cited by 367
Cited by
Neuropathic Pain: From Mechanisms to Treatment
Finnerup, N. B., Kuner, R., & Jensen, T. S. (2021) · Physiological Reviews · doi:10.1152/physrev.00045.2019 · Cited by 1,558
Dworkin, R. H., O'Connor, A. B., Audette, J., Baron, R., Gourlay, G. K., Haanpää, M. L., Kent, J. L., Krane, E. J., LeBel, A. A., Levy, R. M., et al. (2010) · Mayo Clinic Proceedings · doi:10.4065/mcp.2009.0649 · Cited by 1,325
Lauria, G., Hsieh, S. T., Johansson, O., Kennedy, W. R., Leger, J. M., Mellgren, S. I., Nolano, M., Merkies, I. S. J., Polydefkis, M., Smith, A. G., et al. (2010) · European Journal of Neurology · doi:10.1111/j.1468-1331.2010.03023.x · Cited by 864
Self-citationAnand, P., & Bley, K. (2011) · British Journal of Anaesthesia · doi:10.1093/bja/aer260 · Cited by 700
EFNS guidelines on the use of skin biopsy in the diagnosis of peripheral neuropathy
Lauria, G., Cornblath, D. R., Johansson, O., McArthur, J. C., Mellgren, S. I., Nolano, M., Rosenberg, N., & Sommer, C. (2005) · European Journal of Neurology · doi:10.1111/j.1468-1331.2005.01260.x · Cited by 565
Self-citationSurrogate Markers of Small Fiber Damage in Human Diabetic Neuropathy
Quattrini, C., Tavakoli, M., Jeziorska, M., Kallinikos, P., Tesfaye, S., Finnigan, J., Marshall, A., Boulton, A. J. M., Efron, N., & Malik, R. A. (2007) · Diabetes · doi:10.2337/db07-0285 · Cited by 515
Diabetic Peripheral Neuropathy: Epidemiology, Diagnosis, and Pharmacotherapy
Iqbal, Z., Azmi, S., Yadav, R., Ferdousi, M., Kumar, M., Cuthbertson, D. J., Lim, J., Malik, R. A., & Alam, U. (2018) · Clinical Therapeutics · doi:10.1016/j.clinthera.2018.04.001 · Cited by 487
“foot ulceration, and is not recommended in the treatment of painful DPN.(158) Furthermore, currently not included in any published guidance for painful DPN is the 8% capsaicin patch, which was initially tested in patients with postherpetic neuralgia.”
BackgroundMechanism of diabetic neuropathy: Where are we now and where to go?
Yagihashi, S., Mizukami, H., & Sugimoto, K. (2011) · Journal of Diabetes Investigation · doi:10.1111/j.2040-1124.2010.00070.x · Cited by 488
Transient receptor potential ion channels as participants in thermosensation and thermoregulation
Caterina, M. J. (2007) · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.00446.2006 · Cited by 436
Painful Diabetic Neuropathy: Epidemiology, Natural History, Early Diagnosis, and Treatment Options
Veves, A., Backonja, M., & Malik, R. A. (2008) · Pain Medicine · doi:10.1111/j.1526-4637.2007.00347.x · Cited by 375
Unravelling the Mystery of Capsaicin: A Tool to Understand and Treat Pain
O'Neill, J., Brock, C., Olesen, A. E., Andresen, T., Nilsson, M., & Dickenson, A. H. (2012) · Pharmacological Reviews · doi:10.1124/pr.112.006163 · Cited by 348
Peripheral neuropathy in prediabetes and the metabolic syndrome
Stino, A. M., & Smith, A. G. (2017) · Journal of Diabetes Investigation · doi:10.1111/jdi.12650 · Cited by 268
Grayston, R., Czanner, G., Elhadd, K., Goebel, A., Frank, B., Üçeyler, N., Malik, R. A., & Alam, U. (2019) · Seminars in Arthritis and Rheumatism · doi:10.1016/j.semarthrit.2018.08.003 · Cited by 213
Randomized control trial of topical clonidine for treatment of painful diabetic neuropathy
Campbell, C. M., Kipnes, M. S., Stouch, B. C., Brady, K. L., Kelly, M., Schmidt, W. K., Petersen, K. L., Rowbotham, M. C., & Campbell, J. N. (2012) · Pain · doi:10.1016/j.pain.2012.04.014 · Cited by 165
Treating pain in diabetic neuropathy: current and developmental drugs
Alam, U., Sloan, G., & Tesfaye, S. (2020) · Drugs · doi:10.1007/s40265-020-01259-2 · Cited by 104
“At present, we do not recommended capsaicin in the treatment of pDPN for this reason [188].”
BackgroundChowdhury, S. K. R., Dobrowsky, R. T., & Fernyhough, P. (2011) · Mitochondrion · doi:10.1016/j.mito.2011.06.007 · Cited by 82
Metadata
- Authors
- Polydefkis, M., Hauer, P., Sheth, S., Sirdofsky, M., Griffin, J. W., & McArthur, J. C.
- Venue
- Brain
- Publisher
- Oxford University Press (OUP)
- Published
- 2004-07
- Volume
- 127
- Issue
- 7
- Pages
- 1606-1615
- ISSN
- 0006-8950 (ISSN-L)
- 1460-2156
- OpenAlex
- W1981047340
- Cited by
- 375
- References
- 27
- FWCI
- 5.03
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.